NC S152

Requires health benefit plans that cover both orally administered and intravenously administered anticancer drugs to provide coverage on a basis no less favorable for oral drugs than for intravenous drugs.

Prohibits prior authorization, dollar limits, co-payments, coinsurance, deductibles, or other out-of-pocket expenses from applying to orally administered anticancer drugs if they do not apply to intravenously administered or injected anticancer drugs.

Prevents insurers from achieving compliance by reclassifying anticancer drugs or increasing patient cost-sharing; any increases to out-of-pocket expenses for anticancer drugs must also apply to the majority of comparable medical or pharmaceutical benefits.

Effective January 1, 2018, applying to insurance contracts or policies issued, renewed, or amended on or after that date.

Does not become effective if determined to create a state-required benefit exceeding essential health benefits under federal regulations.